We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Chantal Mathieu

Chantal Mathieu MD, PhD

Professor of Medicine, Katholieke Universiteit; Chair, Endocrinology, University Hospital Gasthuisberg, Leuven, Belgium

Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her work in animal models of type 1 diabetes established 1,25-dihydroxyvitamin D3 as an immune modulator and demonstrated the potential of Lactococcus Lactis as a carrier tool for peptides and proteins, which became the basis for a worldwide clinical trial in people with newly diagnosed type 1 diabetes. Her research group was amongst the first to demonstrate the relevance of post-translational modifications of beta-cell peptides and proteins in autoantigen generation in murine and human type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes as well as her educational skills have made her a prominent speaker in international fora. She has promoted shared-care, positioning of diabetes education and reimbursement of novel technologies. Prof. Mathieu is co-author of several consensus papers, including the 2018-19 ADA/EASD Consensus on glucose lowering therapies in type 2 diabetes. Prof. Mathieu leads the INNODIA project and established its Patient Advisory Committee. Prof. Mathieu is also (senior) vice-president of EASD, Chair of postgraduate education and Chair of the European Diabetes Forum.

Disclosures

Chantal Mathieu serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis,  AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Insulet and Zealand Pharma. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for Prof. Mathieu from Medtronic, Novo Nordisk, Sanofi and ActoBio Therapeutics; Prof. Mathieu serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca and Novartis. Financial compensation for these activities has been received by KU Leuven.